

**Remarks**

Applicants wish to thank the Examiner for clarifying the pending rejections identified in the latest office action during a February 27, 2004 phone call. Examiner stated that Applicants are only required to respond to the new grounds for rejection under §112. As such, Applicants understand that the appealed rejections under §103 were removed.

Claims 7, 8, 10, and 18-20 are pending in this application. Examiner stated that the pending claims were rejected because the specification shows in vitro results using the claimed extract to induce expression of phase II enzyme but does not show in vivo results, namely, phase II induction occurring in a subject in need thereof. Applicants have amended the claims to delete reference to “in a subject in need thereof” to expedite allowance of their invention.

Applicants believe the pending claims are in condition for allowance. If, for any reason, Examiner feels that the above amendments and remarks do not put the claims in condition for allowance, please contact the undersigned attorney to resolve any remaining issues.

Date: March 1, 2004

Respectfully Submitted,

BRUVELLI ET AL.



\_\_\_\_\_  
Amy I. Ahn  
Registration No. 44,498  
Attorney for Applicant  
ALTICOR INC. (fka Amway Corporation)  
7575 Fulton Street East  
Ada, Michigan 49355  
(616) 787-8208  
(616) 787-9027 (fax)